CliffBio
small molecule

XARACOLL

BUPIVACAINE HYDROCHLORIDE

Loss of exclusivityJanuary 2033latest FDA-listed patent expiry
CompanyInnocoll Holdings →See this company's full patent-cliff portfolio

Drug detail

Brand nameXARACOLL
Active ingredientBUPIVACAINE HYDROCHLORIDE
Strength100MG
Dosage formIMPLANT
RouteIMPLANTATION
ModalitySmall molecule
FDA approvalAugust 2020
Marketing statusDISCN

Listed patents

PatentExpiresType
11746141January 2033product
RE47826May 2029use U-2949

More from Innocoll Holdings

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.